Welcome
Oligomerix is seeking solutions to major unmet medical needs with over 10 years research experience in helping define the role of tau protein in neurodegenerative diseases and discovering and developing novel therapeutics for Alzheimer’s and related tauopathies.
Role of tau protein in Alzheimer’s disease:
This video shows how the loss of tau protein function leads to structural changes causing the loss of communication between neurons, a defining characteristic of Alzheimer’s disease.Oligomerix has further found that tau acquires toxic functions degrading proteins and disrupting memory formation when it forms small soluble aggregates of tau, tau oligomers.
We are discovering therapeutics that target tau protein loss of function and gain of toxicity
Latest News
October 22, 2018
Oligomerix to present at Society for Neuroscience (SFN) in San Diego on November 5th 2018 at 10:15 AM – Presentation is entitled “In vivo validation of a small molecule inhibitor of tau oligomer formation in htau mice” – Session 268 – Alzheimer’s Disease and Other Dementias: Therapeutic Strategies: Preclinical Animal Models – Rm. SDCC33. See link below for full abstract: https://abstractsonline.com/pp8/#!/4649/presentation/38873
October 17, 2018
Oligomerix Awarded $1.98 Million NIH SBIR Phase IIb Grant to Advance its Lead using Transgenic Models for Alzheimer’s Disease and Frontotemporal Dementia
October 9, 2018
Oligomerix Relocates to Albert Einstein College of Medicine Campus
October 1, 2018
Oligomerix, Inc Awarded $2.49 Million Fast-Track National Institute on Aging SBIR Grant Funding Scale Up and Synthesis of its Lead Compound to Facilitate Initiation of IND-enabling Studies for Alzheimer’s Disease and Related Disorders
January 7, 2018
Oligomerix to attend JP Morgan Healthcare Conference in San Francisco, CA to conduct partnering discussions January 7 – 10, 2018
October 8, 2017
Oligomerix, Inc. Awarded National Institute on Aging SBIR Grant for Development of Alzheimer’s Disease Specific Biomarker
October 8, 2017
Oligomerix to present poster and conduct partnering discussions at Society for Neuroscience in Washington DC – November 12-15, 2017
June 6, 2017
Oligomerix to present poster and conduct partnering discussions at AAIC, London, U.K., July 16 – 20
February 10, 2017
Oligomerix to attend AD/PD 2017 and conduct partnering discussions, Vienna, Austria, March 29 – April 2
January 9, 2017
Oligomerix to attend JP Morgan Healthcare Conference in San Francisco to conduct partnering discussions, CA January 9 – 12, 2017
November 29, 2016
Oligomerix issued US Patent 9,506,051 for tau protease methods & composition using tau self-truncated fragments for drug/antibody discovery
October 11, 2016
Oligomerix issued patent for methods and composition of tau oligomer US Patent 9,464,122 for drug and antibody discovery using tau trimer.
July 24, 2016
Oligomerix to present tau poster at AAIC…